DENTSPLY SIRONA Inc. (BVMF:XRAY34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 10.79B -30.8% |
| Revenue (ttm) | 19.20B -1.0% |
| Net Income | -3.28B |
| EPS | -16.42 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 7.45 |
| Dividend | 1.78 (2.99%) |
| Ex-Dividend Date | Dec 23, 2025 |
| Volume | n/a |
| Average Volume | 654 |
| Open | 59.49 |
| Previous Close | 59.49 |
| Day's Range | 59.49 - 59.49 |
| 52-Week Range | 49.49 - 93.83 |
| Beta | 0.94 |
| RSI | 40.28 |
| Earnings Date | May 5, 2026 |
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as w... [Read more]
Financial Performance
In 2025, DENTSPLY SIRONA's revenue was $3.68 billion, a decrease of -2.98% compared to the previous year's $3.79 billion. Losses were -$598.00 million, -34.29% less than in 2024.
Financial numbers in USD Financial StatementsNews
Dentsply Sirona price target lowered to $17 from $18 at UBS
UBS lowered the firm’s price target on Dentsply Sirona (XRAY) to $17 from $18 and keeps a Buy rating on the shares.
Dentsply Sirona price target lowered to $14 from $16 at Mizuho
Mizuho lowered the firm’s price target on Dentsply Sirona (XRAY) to $14 from $16 and keeps a Neutral rating on the shares.
DENTSPLY SIRONA Earnings Call Transcript: Q1 2026
Q1 2026 results were in line with expectations, with revenue stable and early progress on cost savings and innovation. The company maintained its full-year outlook, focusing on restructuring, debt reduction, and new product launches, while monitoring macro risks and competitive pressures.
Dentsply Sirona Reports First Quarter 2026 Results
News Summary Reported net sales of $880 million Delivered GAAP gross margin of 48.5% , GAAP net loss per share of ($0.05) Achieved adjusted gross margin of 50.7% , adjusted EBITDA margin of 14.7% , ad...
Dentsply Sirona signs distribution agreement with Atlanta Dental Supply
Dentsply Sirona (XRAY) announced an enhanced distribution agreement with Atlanta Dental Supply, under which Atlanta Dental will begin offering Dentsply Sirona’s connected technology solutions portfoli...
Dentsply Sirona Expands U.S. Distribution Footprint Through Enhanced Agreement with Atlanta Dental Supply
CHARLOTTE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona (Nasdaq: XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced an enha...
Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5
CHARLOTTE, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and ...
Dentsply Sirona initiated with a Sell at Citi
Citi initiated coverage of Dentsply Sirona (XRAY) with a Sell rating and $10 price target The firm launched the animal health and dental sectors with a “cautiously optimistic” view. Citi…
Dentsply Sirona price target lowered to $13 from $15 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Dentsply Sirona (XRAY) to $13 from $15 and keeps an In Line rating on the shares. The firm made…
DENTSPLY SIRONA Transcript: Leerink Global Healthcare Conference 2026
Leadership is driving a turnaround with urgent execution, strategic R&D focus, and simplified dealer partnerships. Investments in clinical education, AI, and product modernization are expected to yield results in the second half, with EMEA and Asia Pacific as key growth regions.
Dentsply Sirona, Siemens Healthineers share findings from trial of MRI system
Dentsply Sirona (XRAY) and Siemens Healthineers (SMMNY) share key findings from the clinical trial for validation of their dental-dedicated MRI system. In addition to confirming its significant potent...
First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics
Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI 1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United...
Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2026
CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Leerink Partners G...
Dentsply Sirona price target raised to $18 from $16 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Dentsply Sirona (XRAY) to $18 from $16 and keeps a Buy rating on the shares.
Dentsply Sirona price target raised to $17 from $14 at Barrington
Barrington raised the firm’s price target on Dentsply Sirona (XRAY) to $17 from $14 and keeps an Outperform rating on the shares post the Q4 report. The firm sees some…
Dentsply Sirona price target raised to $16 from $14 at Mizuho
Mizuho analyst Steven Valiquette raised the firm’s price target on Dentsply Sirona (XRAY) to $16 from $14 and keeps a Neutral rating on the shares. The firm updated the company’s…
Dentsply Sirona price target raised to $15 from $12 at Evercore ISI
Evercore ISI raised the firm’s price target on Dentsply Sirona (XRAY) to $15 from $12 and keeps an In Line rating on the shares.
Dentsply Sirona price target raised to $14 from $13 at Stifel
Stifel raised the firm’s price target on Dentsply Sirona (XRAY) to $14 from $13 and keeps a Hold rating on the shares.
Dentsply Sirona price target raised to $14 from $12 at Baird
Baird raised the firm’s price target on Dentsply Sirona (XRAY) to $14 from $12 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results.
Dentsply Sirona announces restructuring plan, expects $55M-$65M in charges
The company’s board of directors approved a restructuring plan. In connection with this plan, the company expects to incur non-recurring charges in the approximate range of $55M to $65M, the…
Dentsply Sirona reports Q4 adjusted EPS 27c, consensus 29c
Reports Q4 revenue $961M, consensus $926.37M. “We delivered results in line with our expectations this quarter while making meaningful progress against our clear, focused priorities and strengthening ...
Dentsply Sirona sees FY26 adjusted EPS $1.40-$1.50, consensus $1.50
Sees FY26 revenue $3.5B-$3.6B, consensus $3.67B. The company said, “For the full year 2026, the Company expects net sales to be in the range of $3.5 billion to $3.6 billion.
DENTSPLY SIRONA Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 results met expectations, with revenue growth in key segments and margin expansion despite tariff headwinds. The 2026 outlook includes lower sales, higher R&D investment, a dividend cut, and a focus on U.S. growth and operational transformation.
Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
News Summary Q4 2025 net sales of $961 million increased 6.2% , constant currency sales increased 2.5% Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodw...
HALPER SADEH LLC ENCOURAGES DENTSPLY SIRONA INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...